On a winning streak, Heron rockets up 30% on PhIIb pain drug data
More than doubling its stock since the first of the year, San Diego’s Heron Therapeutics reported yet another slam dunk Thursday morning with news that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.